732 related articles for article (PubMed ID: 31276706)
21. Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma.
Marrano P; Shago M; Somers GR; Thorner PS
Am J Surg Pathol; 2018 Jun; 42(6):744-749. PubMed ID: 29543677
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.
Latres E; Drobnjak M; Pollack D; Oliva MR; Ramos M; Karpeh M; Woodruff JM; Cordon-Cardo C
Am J Pathol; 1994 Aug; 145(2):345-55. PubMed ID: 8053493
[TBL] [Abstract][Full Text] [Related]
23. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
[TBL] [Abstract][Full Text] [Related]
24. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V; Walter B; Fend F; Overkamp M; Rothermundt C; Lopez CD; Schittenhelm MM; Kampa-Schittenhelm KM
BMC Cancer; 2022 Jul; 22(1):725. PubMed ID: 35780096
[TBL] [Abstract][Full Text] [Related]
25. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
26. Lymphatic dissemination of bone and soft tissue sarcomas: a lymphographic investigation.
Tallroth K
Acta Radiol Suppl; 1976; 349():1-84. PubMed ID: 206099
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.
Mertens F; Fletcher CD; Dal Cin P; De Wever I; Mandahl N; Mitelman F; Rosai J; Rydholm A; Sciot R; Tallini G; Van den Berghe H; Vanni R; Willén H
Genes Chromosomes Cancer; 1998 May; 22(1):16-25. PubMed ID: 9591630
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathology of sarcomas.
Osuna D; de Alava E
Rev Recent Clin Trials; 2009 Jan; 4(1):12-26. PubMed ID: 19149759
[TBL] [Abstract][Full Text] [Related]
29. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Tirode F; Surdez D; Ma X; Parker M; Le Deley MC; Bahrami A; Zhang Z; Lapouble E; Grossetête-Lalami S; Rusch M; Reynaud S; Rio-Frio T; Hedlund E; Wu G; Chen X; Pierron G; Oberlin O; Zaidi S; Lemmon G; Gupta P; Vadodaria B; Easton J; Gut M; Ding L; Mardis ER; Wilson RK; Shurtleff S; Laurence V; Michon J; Marec-Bérard P; Gut I; Downing J; Dyer M; Zhang J; Delattre O;
Cancer Discov; 2014 Nov; 4(11):1342-53. PubMed ID: 25223734
[TBL] [Abstract][Full Text] [Related]
30. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
31. Molecular classification of soft tissue sarcomas and its clinical applications.
Jain S; Xu R; Prieto VG; Lee P
Int J Clin Exp Pathol; 2010 Apr; 3(4):416-28. PubMed ID: 20490332
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
33. Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas.
Liu C; Li B; Li L; Zhang H; Chen Y; Cui X; Hu J; Jiang J; Qi Y; Li F
Int J Clin Exp Pathol; 2015; 8(5):5666-73. PubMed ID: 26191279
[TBL] [Abstract][Full Text] [Related]
34. Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol; 2011 Jan; 18(1):60-74. PubMed ID: 21169739
[TBL] [Abstract][Full Text] [Related]
35. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas.
Taubert H; Würl P; Meye A; Berger D; Thamm B; Neumann K; Hinze R; Schmidt H; Rath FW
Cancer; 1995 Oct; 76(7):1187-96. PubMed ID: 8630896
[TBL] [Abstract][Full Text] [Related]
36. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
37. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors.
Nakayama T; Toguchida J; Wadayama B; Kanoe H; Kotoura Y; Sasaki MS
Int J Cancer; 1995 Oct; 64(5):342-6. PubMed ID: 7591308
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients.
Patiño-García A; Sierrasesúmaga L
Cancer Genet Cytogenet; 1997 Oct; 98(1):50-5. PubMed ID: 9309118
[TBL] [Abstract][Full Text] [Related]
39. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.
Curylova L; Ramos H; Saraiva L; Skoda J
Cancer Lett; 2022 Jan; 525():131-145. PubMed ID: 34742870
[TBL] [Abstract][Full Text] [Related]
40. Soft tissue sarcomas and p53 mutations.
Taubert H; Meye A; Würl P
Mol Med; 1998 Jun; 4(6):365-72. PubMed ID: 10780879
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
